Total submissions: 3
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Women's Health and Genetics/Laboratory Corporation of America, |
RCV001645008 | SCV002766467 | likely pathogenic | Fraser syndrome 1 | 2022-11-03 | criteria provided, single submitter | clinical testing | Variant summary: FRAS1 c.6433C>T (p.Arg2145X) results in a premature termination codon, predicted to cause a truncation of the encoded protein or absence of the protein due to nonsense mediated decay, which are commonly known mechanisms for disease. Truncations downstream of this position have been classified as pathogenic by our laboratory. The variant allele was found at a frequency of 4e-06 in 249164 control chromosomes (gnomAD). c.6433C>T has been reported in the literature in one compound heterozygous individual affected with FRAS1 related disorders (Smogavec_2022). These data do not allow any conclusion about variant significance. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. One ClinVar submitter (evaluation after 2014) cites the variant as pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |
| Center for Genomic Medicine, |
RCV001645008 | SCV004806359 | uncertain significance | Fraser syndrome 1 | 2024-03-25 | criteria provided, single submitter | clinical testing | |
| Institute of Medical Genetics, |
RCV001645008 | SCV001519074 | pathogenic | Fraser syndrome 1 | 2021-03-10 | no assertion criteria provided | clinical testing |